246 related articles for article (PubMed ID: 18836525)
1. Effects of natalizumab treatment on Foxp3+ T regulatory cells.
Stenner MP; Waschbisch A; Buck D; Doerck S; Einsele H; Toyka KV; Wiendl H
PLoS One; 2008 Oct; 3(10):e3319. PubMed ID: 18836525
[TBL] [Abstract][Full Text] [Related]
2. Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells.
Putzki N; Baranwal MK; Tettenborn B; Limmroth V; Kreuzfelder E
Eur Neurol; 2010; 63(5):311-7. PubMed ID: 20453514
[TBL] [Abstract][Full Text] [Related]
3. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level.
Venken K; Hellings N; Thewissen M; Somers V; Hensen K; Rummens JL; Medaer R; Hupperts R; Stinissen P
Immunology; 2008 Jan; 123(1):79-89. PubMed ID: 17897326
[TBL] [Abstract][Full Text] [Related]
4. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.
Venken K; Hellings N; Hensen K; Rummens JL; Medaer R; D'hooghe MB; Dubois B; Raus J; Stinissen P
J Neurosci Res; 2006 Jun; 83(8):1432-46. PubMed ID: 16583400
[TBL] [Abstract][Full Text] [Related]
5. Deficient CD4+CD25+ T regulatory cell function in patients with abdominal aortic aneurysms.
Yin M; Zhang J; Wang Y; Wang S; Böckler D; Duan Z; Xin S
Arterioscler Thromb Vasc Biol; 2010 Sep; 30(9):1825-31. PubMed ID: 20448211
[TBL] [Abstract][Full Text] [Related]
6. Changes of regulatory T cells and FoxP3 gene expression in the aging process and its relationship with lung tumors in humans and mice.
Pan XD; Mao YQ; Zhu LJ; Li J; Xie Y; Wang L; Zhang GB
Chin Med J (Engl); 2012 Jun; 125(11):2004-11. PubMed ID: 22884069
[TBL] [Abstract][Full Text] [Related]
7. Severe immune dysregulation affects CD4⁺CD25(hi)FoxP3⁺ regulatory T cells in HIV-infected patients with low-level CD4 T-cell repopulation despite suppressive highly active antiretroviral therapy.
Méndez-Lagares G; Pozo-Balado MM; Genebat M; García Pergañeda A; Leal M; Pacheco YM
J Infect Dis; 2012 May; 205(10):1501-9. PubMed ID: 22457273
[TBL] [Abstract][Full Text] [Related]
8. No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes.
Brusko T; Wasserfall C; McGrail K; Schatz R; Viener HL; Schatz D; Haller M; Rockell J; Gottlieb P; Clare-Salzler M; Atkinson M
Diabetes; 2007 Mar; 56(3):604-12. PubMed ID: 17327427
[TBL] [Abstract][Full Text] [Related]
9. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study.
Namdar A; Nikbin B; Ghabaee M; Bayati A; Izad M
J Neuroimmunol; 2010 Jan; 218(1-2):120-4. PubMed ID: 19932513
[TBL] [Abstract][Full Text] [Related]
10. CD4+CD25+ regulatory T lymphocytes in malignant pleural effusion.
Chen YQ; Shi HZ; Qin XJ; Mo WN; Liang XD; Huang ZX; Yang HB; Wu C
Am J Respir Crit Care Med; 2005 Dec; 172(11):1434-9. PubMed ID: 16151041
[TBL] [Abstract][Full Text] [Related]
11. Isolation strategies of regulatory T cells for clinical trials: phenotype, function, stability, and expansion capacity.
Ukena SN; Höpting M; Velaga S; Ivanyi P; Grosse J; Baron U; Ganser A; Franzke A
Exp Hematol; 2011 Dec; 39(12):1152-60. PubMed ID: 21864487
[TBL] [Abstract][Full Text] [Related]
12. Dexamethasone upregulates FOXP3 expression without increasing regulatory activity.
Prado C; Gómez J; López P; de Paz B; Gutiérrez C; Suárez A
Immunobiology; 2011 Mar; 216(3):386-92. PubMed ID: 20667622
[TBL] [Abstract][Full Text] [Related]
13. Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis.
Dinh TN; Kyaw TS; Kanellakis P; To K; Tipping P; Toh BH; Bobik A; Agrotis A
Circulation; 2012 Sep; 126(10):1256-66. PubMed ID: 22851544
[TBL] [Abstract][Full Text] [Related]
14. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
Stüve O; Marra CM; Bar-Or A; Niino M; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Jerome KR; Cook L; Grand'Maison F; Hemmer B; Monson NL; Racke MK
Arch Neurol; 2006 Oct; 63(10):1383-7. PubMed ID: 17030653
[TBL] [Abstract][Full Text] [Related]
15. CD4+Foxp3+ regulatory T cells converted by rapamycin from peripheral CD4+CD25(-) naive T cells display more potent regulatory ability in vitro.
Chen JF; Gao J; Zhang D; Wang ZH; Zhu JY
Chin Med J (Engl); 2010 Apr; 123(7):942-8. PubMed ID: 20497692
[TBL] [Abstract][Full Text] [Related]
16. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
Wipfler P; Oppermann K; Pilz G; Afazel S; Haschke-Becher E; Harrer A; Huemer M; Kunz A; Golaszewski S; Staffen W; Ladurner G; Kraus J
Mult Scler; 2011 Jan; 17(1):16-23. PubMed ID: 20937631
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo expanded regulatory T cells CD4
Lifshitz GV; Zhdanov DD; Lokhonina AV; Eliseeva DD; Lyssuck EY; Zavalishin IA; Bykovskaia SN
Autoimmunity; 2016 Sep; 49(6):388-396. PubMed ID: 27424664
[TBL] [Abstract][Full Text] [Related]
18. Stimulation of α7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro.
Wang DW; Zhou RB; Yao YM; Zhu XM; Yin YM; Zhao GJ; Dong N; Sheng ZY
J Pharmacol Exp Ther; 2010 Dec; 335(3):553-61. PubMed ID: 20843956
[TBL] [Abstract][Full Text] [Related]
19. Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents.
de Vries IJ; Castelli C; Huygens C; Jacobs JF; Stockis J; Schuler-Thurner B; Adema GJ; Punt CJ; Rivoltini L; Schuler G; Coulie PG; Lucas S
Clin Cancer Res; 2011 Feb; 17(4):841-8. PubMed ID: 21177412
[TBL] [Abstract][Full Text] [Related]
20. Neutralization of interleukin-10 or transforming growth factor-β decreases the percentages of CD4+ CD25+ Foxp3+ regulatory T cells in septic mice, thereby leading to an improved survival.
Hiraki S; Ono S; Tsujimoto H; Kinoshita M; Takahata R; Miyazaki H; Saitoh D; Hase K
Surgery; 2012 Feb; 151(2):313-22. PubMed ID: 21982068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
